# Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

> **NCT07382726** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Adagrasib
- **DRUG:** Iza-bren

## Key facts

- **NCT ID:** NCT07382726
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-24
- **Final completion:** 2029-12-24
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382726, "Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07382726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*